# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) co...
Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target fro...
This allows Teva to end this historical income tax issue, and to continue to focus on its commitment to the health of patients ...
Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. marke...
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copax...
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceu...
Teva sues Corcept over mifepristone 'monopoly' for rare disorder | Reuters